Skip to content

Study · Non-randomized trial · n = 35 · 1994

12 results

Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.

Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS

The Journal of clinical investigation1 Mar 1994Cited by 87 (Europe PMC)

PMID8132753 (opens in a new tab)PMCIDPMC294058 (opens in a new tab)DOI10.1172/jci117065 (opens in a new tab)PepBankPUB-08132753
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy adults, rhIGF-I and insulin increased glucose uptake in a nearly identical fashion.

    In plain wordsIn healthy adults, rhIGF-I and insulin increased glucose uptake similarly.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeGlucose uptake
    Study

    n = 35

    Comparator
    Insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Source sentences

    Summary
    The metabolic responses to rhIGF-I and insulin were remarkably similar: not only did both hormones increase glucose uptake and oxidation in a nearly identical fashion
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy adults, rhIGF-I and insulin increased glucose oxidation in a nearly identical fashion.

    In plain wordsIn healthy adults, rhIGF-I and insulin increased glucose oxidation similarly.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeGlucose oxidation
    Study

    n = 35

    Comparator
    Insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Source sentences

    Summary
    The metabolic responses to rhIGF-I and insulin were remarkably similar: not only did both hormones increase glucose uptake and oxidation in a nearly identical fashion
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy adults, rhIGF-I and insulin similarly suppressed glucose production.

    In plain wordsIn healthy adults, rhIGF-I and insulin similarly reduced glucose production.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeGlucose production
    Study

    n = 35

    Comparator
    Insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Source sentences

    Summary
    but they also produced similar suppression of glucose production, free fatty acid levels, and fat oxidation rates.
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy adults, rhIGF-I and insulin similarly suppressed free fatty acid levels.

    In plain wordsIn healthy adults, rhIGF-I and insulin similarly reduced free fatty acid levels.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeFree fatty acid levels
    Study

    n = 35

    Comparator
    Insulin
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Source sentences

    Summary
    but they also produced similar suppression of glucose production, free fatty acid levels, and fat oxidation rates.
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy adults, rhIGF-I and insulin similarly suppressed fat oxidation rates.

    In plain wordsIn healthy adults, rhIGF-I and insulin similarly reduced fat oxidation rates.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeFat oxidation
    Study

    n = 35

    Comparator
    Insulin
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Source sentences

    Summary
    but they also produced similar suppression of glucose production, free fatty acid levels, and fat oxidation rates.
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects
  6. 06HumanNon-randomized trialMechanism

    In healthy adults, rhIGF-I lowered amino acid levels more than insulin.

    In plain wordsIn healthy adults, rhIGF-I lowered amino acid levels more than insulin.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseAmino acid levels
    Study

    n = 35

    Comparator
    Insulin
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Measurements

    P value for amino acid lowering, rhIGF-I versus insulin
    < 0.004
    rhIGF-I versus insulin, healthy adults

    Source sentences

    Summary
    In contrast, rhIGF-I had a more pronounced amino acid-lowering effect than did insulin (P < 0.004).
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects
  7. 07HumanNon-randomized trialMechanism

    In healthy adults, age did not alter the response to rhIGF-I.

    In plain wordsIn healthy adults, age did not alter the response to rhIGF-I.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeMetabolic response by age
    Study

    n = 35

    Comparator
    Younger subjects
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Source sentences

    Summary
    Age did not alter the response to rhIGF-I.
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects
  8. 08HumanNon-randomized trialMechanism

    In healthy younger adults, rhIGF-I suppressed insulin by 19-33%.

    In plain wordsIn healthy younger adults, rhIGF-I reduced insulin by 19-33%.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseInsulin suppression
    Study

    n = 21

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Measurements

    Insulin suppression
    19 to 33%
    younger subjects, rhIGF-I infusion
    P value for insulin suppression
    < 0.02 unitless
    younger subjects, rhIGF-I infusion versus baseline

    Source sentences

    Summary
    In younger subjects, rhIGF-I infusions suppressed insulin by 19-33%, C-peptide by 47-59% and glucagon by 33-47% (all, P < 0.02).
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects
  9. 09HumanNon-randomized trialMechanism

    In healthy younger adults, rhIGF-I suppressed C-peptide by 47-59%.

    In plain wordsIn healthy younger adults, rhIGF-I reduced C-peptide by 47-59%.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseC-peptide suppression
    Study

    n = 21

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Measurements

    C-peptide suppression
    47 to 59%
    younger subjects, rhIGF-I infusion
    P value for C-peptide suppression
    < 0.02 unitless
    younger subjects, rhIGF-I infusion versus baseline

    Source sentences

    Summary
    In younger subjects, rhIGF-I infusions suppressed insulin by 19-33%, C-peptide by 47-59% and glucagon by 33-47% (all, P < 0.02).
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects
  10. 10HumanNon-randomized trialMechanism

    In healthy younger adults, rhIGF-I suppressed glucagon by 33-47%.

    In plain wordsIn healthy younger adults, rhIGF-I reduced glucagon by 33-47%.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseGlucagon suppression
    Study

    n = 21

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Measurements

    Glucagon suppression
    33 to 47%
    younger subjects, rhIGF-I infusion
    P value for glucagon suppression
    < 0.02 unitless
    younger subjects, rhIGF-I infusion versus baseline

    Source sentences

    Summary
    In younger subjects, rhIGF-I infusions suppressed insulin by 19-33%, C-peptide by 47-59% and glucagon by 33-47% (all, P < 0.02).
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects
  11. 11HumanNon-randomized trialMechanism

    In healthy adults in paired euglycemic clamp studies, rhIGF-I suppressed C-peptide more than insulin did.

    In plain wordsIn healthy adults, rhIGF-I lowered C-peptide more than insulin did.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseC-peptide suppression versus insulin
    Study

    n: not reported in source

    Comparator
    Insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.4, and 0.8 micrograms/kg.min · infusion · 3 hAs given in this study (human).

    Measurements

    P value for C-peptide suppression
    < 0.007 unitless
    insulin versus rhIGF-I in paired euglycemic clamp studies

    Source sentences

    Summary
    The suppression of C-peptide was less pronounced with insulin than with rhIGF-I (P < 0.007).
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 12HumanEndogenous levelObservational studyOther

    In healthy middle-aged adults, basal IGF-I levels were 44% lower than in younger adults.

    In plain wordsIn healthy middle-aged adults, natural IGF-I levels were 44% lower than in younger adults.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseBasal IGF-I by age
    Study

    n = 35

    Comparator
    Younger subjects
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Basal IGF-I difference, middle-aged vs younger
    44 % lower
    healthy middle-aged vs younger subjects, P < 0.0001

    Source sentences

    Summary
    In middle-aged subjects, basal IGF-I levels were 44% lower (P < 0.0001) whereas basal insulin and C-peptide were 20-25% higher than in younger subjects.
    1 context sentence
    Summary · context
    The actions of recombinant human insulin-like growth factor-I (rhIGF-I) and insulin were compared in 21 healthy young (24 +/- 1 yr) and 14 healthy middle-aged (48 +/- 2 yr) subjects

    This result measures the body's own IGF-1 (mecasermin). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.